Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 28, 2015 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma to Present at the Jefferies 2015 Global Healthcare Conference

MALVERN, Pa., May 28, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of...
May 12, 2015 18:03 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports First Quarter 2015 Financial Results

Strengthened Company with Acquisition of Phase III-Ready IV/IM Meloxicam, Cash Flow Positive Manufacturing/Formulation Business from Alkermes Encouraging Dex-IN Interim Analysis Results Support...
April 13, 2015 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Completes Acquisition of IV/IM Meloxicam and cGMP Manufacturing Facility and Business Unit From Alkermes

- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product - Phase III-Ready, Long-Acting Injectable Meloxicam Has...
April 09, 2015 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Announces Update on On-Going Phase II Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

MALVERN, Pa., April 9, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute...
March 25, 2015 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports Fourth Quarter and Full Year 2014 Financial Results

‒ On Track to Report Top-Line Phase II Data from Dex-IN Post Op Day 1 Trial in Mid 2015 ‒ ‒ Strengthened Company with Expected Acquisition of Phase III-Ready IV/IM Meloxicam,...
March 09, 2015 06:00 ET | Source: Societal CDMO, Inc.

Recro Pharma to Acquire IV/IM Meloxicam and Gainesville, GA GMP Manufacturing Facility and Business Unit From Alkermes

- Transformative Acquisition Diversifies Recro Pharma's Development Risk with Second, Complementary Acute Pain Product - Phase III-Ready, Long-Acting Injectable Meloxicam Has...
February 03, 2015 08:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Enters Into Common Stock Purchase Agreement With Aspire Capital

MALVERN, Pa., Feb. 3, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
February 02, 2015 16:22 ET | Source: Societal CDMO, Inc.

Recro Pharma to Present at the 17th Annual BIO CEO & Investor Conference

MALVERN, Pa., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of acute post...
November 10, 2014 07:00 ET | Source: Societal CDMO, Inc.

Recro Pharma Reports Third Quarter 2014 Financial Results

MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...
October 29, 2014 16:05 ET | Source: Societal CDMO, Inc.

Recro Pharma Announces Dosing of First Patient in Phase II REC-14-013 Clinical Trial of Dex-IN for Treatment of Acute Pain on Day 1 Following Surgery

MALVERN, Pa., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain,...